Cognitive behavioral therapy interventions were statistically and clinically superior to self-help leaflets in the treatment of anxiety in patients with COPD.
Patients with COPD who were considered frail were more likely to have lower quality of life, increased rate and length of hospitalization, and a higher rate of mortality.
Compared with usual care, a comprehensive 3-month program combining transition and long-term self-management support for patients with COPD led to significantly fewer COPD-related hospitalizations and greater quality of life.
A strong dose-response relationship was seen in never-smokers aged 50 and older.
Ottawa COPD Risk Scale is valid for predicting short-term serious outcomes for patients in the emergency department.
Blood eosinophil concentrations could be used to target patients with chronic obstructive pulmonary disease who are likely to respond to initial long-acting bronchodilator therapy.
Living in a rural community was a predictor for COPD prevalence, whether the individual had a history of smoking or was a current smoker.
The presence of COPD is linked to higher all-cause mortality and cardiac death at 24 hours in high-risk patients who present with ventricular tachyarrhythmias and sudden cardiac arrest.
Decreasing alpha diversity in the microbiome profile of sputum samples of patients hospitalized with COPD acute exacerbations was associated with increased 1-year mortality.
Nocturnal hypoxemia, along with COPD, increased the risk for cardiovascular events and mortality in female patients with suspected obstructive sleep apnea.
Healthcare providers should educate all patients with COPD about their flight-related risks and the need to seek medical advice before flying.
Bronchoscopic lung volume reduction with valve replacement shows the most promise for improving lung function, exercise tolerance, and quality of life in patients with advanced emphysema.
Compared with a combination treatment of LABA/LAMA, ICS/LABA/LAMA combination therapy was associated with a significantly greater pooled risk reduction in COPD exacerbation.
Few individuals hospitalized for COPD receive pulmonary rehabilitation.
Three-dimensional "super clusters" in patients with COPD could play a role in the progression of COPD to emphysema.
There may an increased risk for tuberculosis in patients with COPD within 3 years of inhaled corticosteroid use.
The FDA has approved Yupelri inhalation solution for the maintenance treatment of patients with COPD.
The overall rate of asthma-COPD overlap was 3.8%, with a maximum prevalence of 7.8% in Matlab, Bangladesh.
Adults with COPD treated with both inhaled corticosteroids and low-dose theophylline as adjunct therapy did not have fewer exacerbations compared with patients treated with inhaled corticosteroids only.
Half of patients with COPD report use of inhaler medications that are not in alignment with the current treatment recommendations.